|
|
|
| Effects of Docetaxel Combined with Ifosfamide on Expression of Cyclin D1 and GADD153 in Ovarian Cancer CAOV3 Cells |
| GE Qian-qian |
| Huai'an First Hospital Affiliated to Nanjing Medical University 223000 |
|
|
|
|
Abstract 【Objective】To investigate the effects of docetaxel combined with ifosfamide on cyclin D1, growth inhibition and DNA damage-inducible protein 153 (GADD153) expression in ovarian cancer CAOV3 cells. 【Methods】The ovarian cancer CAOV3 cells were divided into three groups, which were recorded as blank control group, docetaxel group and combination group. Cells in the blank control group was routinely added with regular tissue culture medium. The docetaxel group was given single docetaxel intervention and the combination group was treated with docetaxel and ifosfamide. All treatments in three groups were applied for 72 hours. The cell proliferation rates at different time points were measured by MTT assay. The cell cycle was determined by flow cytometry with PI staining. The expression levels of cyclinD1 and GADD153 were detected by Western Blot. 【Results】 The cell proliferation rate of the combination group was higher than that of the docetaxel group and the blank control group at 24h, 36h and 72h (P<0.05). The G0/G1 phase of ovarian cancer CAOV3 cells in the combination group was lower than that in the docetaxel group and the blank control group; and the S phase in the combination group was higher than that in docetaxel group and blank control group (P<0.05). The level of cyclin D1 was lower but GADD153 was higher than those in the docetaxel group and the blank control group at 24h, 36h and 72h after intervention. P<0.05). 【Conclusion】Docetaxel combined with ifosfamide can induce and promote apoptosis of ovarian cancer CAOV3 cells through expression changes of cyclin D1 and GADD153 proteins.
|
|
Received: 17 December 2018
|
|
|
|
|
|
[1] Tambo Y,Hosomi Y,Sakai H,et al. Phase Ⅰ/Ⅱ study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy[J].Invest New Drugs,2017, 35(2):1-10.
[2] 秦海霞,崔红凯,潘莹,etal.miR-335靶向Rho相关卷曲螺旋形成蛋白激酶1对卵巢癌细胞增殖的影响[J].中国生物工程杂志,2016,36(6):24-31.
[3] Ranjan A. Biodistribution and efficacy of low temperature-sensitive liposome encapsulated docetaxel combined with mild hyperthermia in a mouse model of prostate cancer[J].Pharmaceutical Res,2016, 33(10):1-11.
[4] 魏蔚,刘玉华,刘守燕.Toll样受体4特异性拮抗剂TAK-242对人卵巢癌细胞株SKOV-3增殖、凋亡的影响及其机制[J].山东医药,2017,57(19):37-39.
[5] 张孟伟,秦亚光,王亚秋,等.铂类耐药复发转移性卵巢癌贝伐单抗联合白蛋白结合型紫杉醇治疗临床观察[J].中华肿瘤防治杂志,2016,23(5):331-334.
[6] Tiainen L, Tanner M, Lahdenper O, et al. Bevacizumab combined with docetaxel or paclitaxel as first-line treatment of HER2-negative metastatic breast cancer[J].Anticancer Res,2016, 36(12):6431.
[7] 王婉,胡倩倩,杨文静.多西他赛联合奈达铂对上皮性卵巢癌患者血清LPA、CA199、CEA、白细胞介素及免疫功能的影响[J].海南医学院学报,2016,22(20):2478-2481.
[8] 胡钧文,田源.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌临床对比研究[J].国外医药抗生素分册,2017,38(1):26-28.
[9] 胡远强,张永波,王华,等.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效和安全性比较[J].中国药房,2016,27(24):3353-3356. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(9): 1848-1850. |
|
|
|
|
2019, Vol. 36 
